LAS VEGAS, Dec. 18, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it will demonstrate how Automobili Lamborghini S.p.A can leverage the Intelligent Product Lifecycle to improve the ...

All right. Thanks, everyone, for joining us. My name is Sterling Auty. I'm Vice Chairman of Software Investment Banking here at Barclays. Really happy to have with us the team from PTC for our next ...

PTC, Inc. is a global software company. Its products include Windchill, Creo, ThingWorx, Vuforia, Codebeamer, Arbortext, Arena, and Onshape. The company was founded ...

- Import documents directly into Codebeamer through IQNECT, automatically breaking content into structured, editable tracker items for full traceability and AI-assisted editing. 2. End-User Admin ...

Private equity firm TPG is to buy Kepware and ThingWorx from PTC for up to $725 million. It marks a final shift in PTC’s Industry 4.0 strategy, and a tightening of focus on its industrial PLM ...

PTC is selling off its IoT businesses, Kepware and ThingWorx, in order to hone its focus on SaaS and AI, according to CEO Neil Barua, as the conglomerate announced a sale of the operations to asset ...

TPG has agreed to acquire PTC’s industrial connectivity and IoT businesses. No financial terms were disclosed. Headquartered in Boston, PTC is a software company. Neil Barua serves as president and ...

Agentic AI advancements in ServiceMax AI accelerate work order execution and enable improvements in first-time fix rates Agentic AI advancements in Servigistics expand AI-driven intelligence for ...

Well, great to be here. Thank you, Tyler, and glad to make the trip down. First of all, PTC, global software company. We help our customers who build amazing products, design, build and maintain those ...

This software company's underlying growth rate is a lot stronger than the headline numbers indicate. ARR represents the "annualized value of our portfolio of active subscription software, SaaS, ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...